Department of Hyperbaric Oxygen, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Laboratory of Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Thorac Cancer. 2017 Nov;8(6):710-713. doi: 10.1111/1759-7714.12495. Epub 2017 Aug 29.
Invasive mucinous adenocarcinoma (IMA) is an uncommon entity in the lung, with a poor prognosis. Multifocal IMA of the lung is even more unusual, and there is little experience with effective treatments. Herein, we present a case of multifocal IMA diagnosed in a 36 year-old man by video-assisted thoracoscopic surgery. A right middle lobe and a nodule in the right upper lobe were resected, as were mediastinal lymph nodes, leaving behind an autonomous right lower lobe nodule. To explore the feasibility of molecular treatment, next-generation sequencing of genetic mutations was performed after four cycles of chemotherapy (pemetrexed + cisplatin). Ultimately, a KIAA1468-RET fusion gene was detected at a disproportionate level (~67.3%), indicating that targeted therapy may be efficacious in treating this disease.
肺浸润性黏液性腺癌（IMA）是一种罕见的肺部实体瘤，预后较差。肺多灶性 IMA 更为罕见，且对有效治疗方法的经验很少。在此，我们介绍了 1 例经电视辅助胸腔镜手术诊断的 36 岁男性多灶性 IMA 病例。切除了右中叶和右上叶的结节，以及纵隔淋巴结，仅留下自主的右下肺结节。为了探索分子治疗的可行性，在进行了 4 个周期的化疗（培美曲塞+顺铂）后，对遗传突变进行了下一代测序。最终，检测到 KIAA1468-RET 融合基因水平异常升高（约 67.3%），表明针对该疾病的靶向治疗可能有效。
